Rainmed Medical Limited (02297.HK)

Rainmed Medical Ltd. operates as a medical device company. The company is headquartered in Suzhou, Jiangsu and currently employs 214 full-time employees. The company went IPO on 2022-07-08. The firm is primarily engaged in research and development, manufacturing and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) system, coronary angiography-derived index of microvascular resistance (caIMR) system and in vitro diagnostic (IVD) products. The Company’s core products, caFFR system and caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. The firm mainly operates its businesses in the domestic and overseas markets.